Equities

PAVmed Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PAVM:NAQ

PAVmed Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)10.46
  • Today's Change-0.50 / -4.56%
  • Shares traded76.00
  • 1 Year change-51.51%
  • Beta0.9373
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

  • Revenue in USD (TTM)29.00k
  • Net income in USD-595.00k
  • Incorporated2014
  • Employees39.00
  • Location
    PAVmed Inc360 Madison Avenue, 25Th FloorNEW YORK 10017United StatesUSA
  • Phone+1 (212) 949-4319
  • Fax+1 (302) 655-5049
  • Websitehttps://pavmed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Meihua International Medical Tech Co Ltd89.55m9.27m8.42m619.000.28780.01890.85730.094134.1234.12302.14520.790.484453.651.05144,664.905.029.695.9011.6934.3137.0210.3513.995.6689.960.06490.00-0.19494.01-6.73-6.81-56.87--
SeaStar Medical Holding Corp881.00k-13.67m8.44m19.00--0.696--9.57-16.43-16.430.68743.360.0876--6.1046,368.42-135.86---290.37--95.35---1,551.08--3.64--0.00------5.34------
Bioelectronics Corp1.61m-289.82k8.65m9.00------5.37-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
Nexalin Technology Inc156.94k-8.68m8.93m6.00--1.83--56.88-0.6345-0.63450.01090.26220.03020.300413.5926,156.67-167.17-166.16-178.46-334.5469.5176.06-5,530.09-1,178.9513.03--0.00--52.34-4.04-63.64------
AccuStem Sciences Inc0.00-1.61m9.16m2.00---------0.1163-0.11630.00-0.18110.00----0.00-192.46--------------------------26.60------
ALR Technologies SG Ltd9.49k-8.00m9.68m6.00------1,020.23-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
HeartSciences Inc8.67k-9.04m10.07m15.00--2.33--1,162.04-6.95-6.950.00571.360.00130.0056--578.00-131.22-145.78-202.97-316.2157.9056.93-104,225.80-42,610.782.00-10.000.1068---76.61-41.63-32.70--21.46--
PAVmed Inc29.00k-595.00k10.41m39.0028.2628.53--359.13-0.6822-0.68220.00051.550.0009--3.05743.594.17-115.648.14-8,726.29-520.69--4,931.04-3,891.34----0.2111--22.15--148.24--15.12--
QHSLab Inc2.61m-386.75k10.49m4.00------4.01-0.0373-0.03730.1997-0.05421.4926.3812.80653,480.00-22.10-39.97---284.7966.3755.22-14.80-44.620.17140.30381.63--51.31--44.65------
Dror Ortho-Design Inc0.00-3.12m10.72m3.00---------0.0033-0.00330.00-0.00240.00----0.00-405.89-214.68---759.55-------276,220.70---69.87---------61.89------
Beyond Air Inc5.80m-36.70m10.95m61.00--0.6542--1.89-7.54-7.541.151.590.13822.608.0195,114.76-89.86-81.28-105.60-103.40-6.70---650.33-4,167.723.73-16.500.4351--219.6721.6622.60--166.66--
SINTX Technologies Inc1.27m-16.56m11.25m20.00--2.60--8.86-6.93-6.930.58941.130.11211.345.5263,500.00-86.86-51.41-121.23-64.3452.0566.36-775.12-575.951.60-302.730.0143--9.9033.18-33.06--36.24--
Movano Inc500.00k-17.05m11.32m32.00------22.64-6.54-6.540.0883-2.040.04850.82163.5115,625.00-165.32-159.40-360.23-208.33-270.20---3,409.60-11,662.690.3451-12.462.32------18.97---9.25--
REMSleep Holdings Inc12.27k-3.01m11.49m6.00--47.62--936.05-0.0019-0.00190.000010.00020.01930.8251.51---472.04-107.16-671.87-177.2194.87---24,509.54-1,456.221.73--0.2146---42.47--39.36--5.18--
BioNano Genomics Inc28.72m-38.59m11.60m98.00--0.2228--0.4039-737.92-737.929.995.120.34511.455.84293,061.20-46.37-58.31-69.84-72.5345.9718.60-134.36-487.421.82--0.07---14.7924.8951.82--11.02--
Data as of Feb 11 2026. Currency figures normalised to PAVmed Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.